Warren Buffett and Greg Abel Keep Overlooking This Stock -- but It's One of the Most Berkshire-Ready Picks on the Market
Even if Berkshire Hathaway never scoops up a stake on this largely overlooked and mostly unloved name, that doesn't mean it doesn't have a place in your portfolio.
Overview
Berkshire Hathaway's (NYSE: BRKA) (NYSE: BRKB) second-quarter 13F is now officially filed, disclosing all the stock trades it made during the quarter, and ultimately offering a snapshot of the conglomerate's current stock portfolio.
No real surprises either. Although Berkshire was a net buyer for the first time in a long time, the additions were expansions of existing positions, or new purchases that make enough sense.
Details
There's one name arguably worth Warren Buffett's and Greg Abel's consideration, however, that still isn't a Berkshire Hathaway holding. That's drugmaker Pfizer (NYSE: PFE). Here's why Berkshire should buy it, and why you might want to even if Abel or Buffett don't end up adding it to Berkshire Hathaway's portfolio anytime soon.
Source
Originally published at www.fool.com.